Developer docs
API playgroundTry for free, no card

Search company profiles

Ascidian Therapeutics

Full company profile

uuid0000hsm

Namestring
Ascidian Therapeutics
Legal namestring
Ascidian Therapeutics, Inc.
Websiteurl
ascidian-tx.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Ascidian Therapeutics is a clinical-stage biotechnology company developing a first-of-its-kind RNA exon editing platform to treat the underlying genetic causes of diseases by replacing disease-causing exons with wild-type exons at the RNA level, without modifying DNA. The platform is inspired by ascidian (sea squirt) trans-splicing biology and is built around pre-mRNA trans-splicing combined with high-throughput molecular biology, computational biology, structure-based RNA design, and an AI/ML-enabled RNA discovery engine. The lead therapeutic candidate, ACDN-01, is a single-AAV-vector RNA exon editor for ABCA4 retinopathies including Stargardt disease and is currently in the Phase 1/2 STELLAR trial, with adult dose escalation completed and pediatric expansion underway; preclinical pipeline includes an MSH3 splice-modulation program targeting Huntington's disease and other repeat expansion disorders.

The company is headquartered in Boston, MA, employs 11-50 people, and is backed by Apple Tree Partners, which founded the company in October 2022 and led both the $50M Series A and $40M Series A extension. Ascidian's business model is built on strategic research collaborations and licensing agreements with major pharmaceutical companies rather than direct product sales. Key deals include a June 2024 collaboration with Roche (up to $1.8B with $42M upfront) for neurological diseases and a June 2026 collaboration with Eli Lilly (up to $1.9B) for inherited kidney diseases, with Lilly and Roche handling clinical development, manufacturing, and commercialization for partnered indications. Manufacturing for ACDN-01 is supported by a January 2026 partnership with Forge Biologics using its cGMP FUEL platform. Customer segments are disease-defined (Stargardt/ABCA4 retinopathies, neurological diseases, monogenic kidney diseases, neuromuscular disorders), and pricing for any future approved therapeutics is not publicly disclosed as the company remains pre-revenue.

Short descriptiontext

Ascidian Therapeutics is a clinical-stage biotechnology company developing RNA exon editing therapeutics for genetic diseases. Its lead program, ACDN-01, targets Stargardt disease, with partnered programs in neurological and kidney diseases via Roche and Eli Lilly.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
RNA exon editing, gene therapy, RNA therapeutics, clinical-stage biotechnology, genetic disease treatment
Industry1 code
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
RNA Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

Ascidian generates revenue through strategic research collaborations and licensing agreements with major pharmaceutical companies. These deals include upfront payments, development and commercial milestones, and royalties. Notable deals include Eli Lilly partnership (up to $1.9B for kidney diseases) and Roche partnership (up to $1.8B for neurological diseases).

fiercebiotech.com
2Future Drug Commercialization
TypeOne Time License
Description

Pre-revenue clinical stage company. Future revenue potential from commercialization of RNA exon editing therapeutics, including ACDN-01 for Stargardt disease and other pipeline programs in retinal, neurological, neuromuscular, and kidney disease indications.

biospace.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Ascidian Therapeutics develops RNA exon editing therapeutics that replace disease-causing exons with wild-type exons at the RNA level using pre-mRNA trans-splicing technology. The platform enables treatment of large genes and genes with high mutational variance that are beyond the reach of existing DNA editing approaches, without modifying DNA or requiring foreign enzymes. Its lead candidate ACDN-01 targets ABCA4 retinopathies including Stargardt disease and is in Phase 1/2 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Completed dose escalation portion of Phase 1/2 STELLAR trial with 10 adult participants ages 18-77
+2 more records
Product overview1 text field

Ascidian Therapeutics is developing a new class of RNA exon editing therapeutics to treat the underlying causes of genetic diseases. The company's platform technology enables editing and replacement of disease-causing RNA exons, producing full-length functional proteins. The lead therapeutic candidate ACDN-01 targets ABCA4 retinopathies including Stargardt disease and is in Phase 1/2 clinical trials. Additional programs include MSH3 for Huntington's disease and repeat expansion disorders. Partnered programs with Roche (neurological diseases) and Eli Lilly (kidney diseases) leverage the platform for additional therapeutic areas. The company operates with manufacturing partnerships including Forge Biologics for cGMP production.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

Global research and licensing agreement worth up to $1.9 billion for discovery and development of RNA exon editing therapies for kidney diseases. Ascidian leads discovery and selected preclinical activities while Lilly handles clinical development, manufacturing, and commercialization with exclusive rights to Ascidian's exon editing platform for undisclosed kidney disease targets. The partnership targets monogenic kidney diseases affecting over 3.5 million Americans.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-01-07
Description

Strategic manufacturing partnership for ACDN-01, Ascidian's lead RNA exon editing therapy for Stargardt disease. Forge Biologics provides process development, toxicology, and cGMP manufacturing services using proprietary FUEL platform at its 200,000-square-foot facility in Columbus, Ohio.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-06-18
Description

Partnership potentially worth up to $1.8 billion for discovery and development of RNA exon editing therapeutics targeting neurological diseases. Ascidian received $42 million upfront payment from Roche for the neuro-focused collaboration, with potential additional milestone and royalty payments.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

RNA-focused biotech developing Axiomer RNA editing technology and other RNA-based therapies for inherited retinal diseases and other genetic disorders. Direct competitor in RNA editing for ophthalmology indications.

TypeEmerging player
Description

Clinical-stage company developing gene therapies based on protein trans-splicing (similar biological concept to Ascidian's RNA trans-splicing). Direct mechanistic parallel in exon replacement for genetic diseases.

TypeBroad incumbent
Description

Clinical-stage company developing base editing and prime editing therapies for genetic diseases. Competes in the broader genetic medicine editing space where Ascidian's exon editing is positioned as a complementary modality for large-gene targets.

TypeBroad incumbent
Description

Clinical-stage CRISPR/Cas9 gene editing company developing in vivo and ex vivo therapies for genetic diseases. Represents the incumbent DNA-editing approach that Ascidian's RNA exon editing is positioned to complement for large-gene targets.

TypeBroad incumbent
Description

Clinical-stage CRISPR-based gene editing company with programs in ophthalmology and genetic diseases. Competes in the broader genomic medicine space where Ascidian's RNA exon editing offers a non-DNA editing alternative.

TypeEmerging player
Description

Clinical-stage company developing oligonucleotide therapies for muscle diseases, founded by Romesh Subramanian (also Ascidian's co-founder). Closely related through founder DNA and overlapping RNA-based therapeutic platform.

TypeEmerging player
Description

Preclinical RNA editing company leveraging AI/ML-based platform for RNA-targeted therapies. Competes with Ascidian's AI-enabled RNA discovery platform in computational RNA therapeutic design.

TypeDirect peer
Description

Clinical-stage biotech developing antisense oligonucleotide (ASO) therapies that increase protein production by modulating RNA splicing, including for genetic diseases such as Dravet syndrome. Direct competitor in RNA-targeted precision medicines for genetic disorders.

TypeEmerging player
Description

Preclinical/early clinical company developing RNA editing therapeutics using ADAR-mediated approaches for genetic diseases. Competes with Ascidian in the RNA editing modality space, focused on high-throughput platform-based RNA editing.

TypeDirect peer
Description

Clinical-stage RNA therapeutics company developing RNA editing and splice-modulating oligonucleotides for genetic diseases. Direct competitor in RNA-targeted modalities with similar programs in ophthalmology and rare genetic diseases.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ascidian Therapeutics

RNA Therapeuticsascidian-tx.com

Ascidian Therapeutics is a clinical-stage biotechnology company developing RNA exon editing therapeutics for genetic diseases. Its lead program, ACDN-01, targets Stargardt disease, with partnered programs in neurological and kidney diseases via Roche and Eli Lilly.

What Ascidian Therapeutics does

Ascidian Therapeutics is a clinical-stage biotechnology company developing a first-of-its-kind RNA exon editing platform to treat the underlying genetic causes of diseases by replacing disease-causing exons with wild-type exons at the RNA level, without modifying DNA. The platform is inspired by ascidian (sea squirt) trans-splicing biology and is built around pre-mRNA trans-splicing combined with high-throughput molecular biology, computational biology, structure-based RNA design, and an AI/ML-enabled RNA discovery engine. The lead therapeutic candidate, ACDN-01, is a single-AAV-vector RNA exon editor for ABCA4 retinopathies including Stargardt disease and is currently in the Phase 1/2 STELLAR trial, with adult dose escalation completed and pediatric expansion underway; preclinical pipeline includes an MSH3 splice-modulation program targeting Huntington's disease and other repeat expansion disorders.

The company is headquartered in Boston, MA, employs 11-50 people, and is backed by Apple Tree Partners, which founded the company in October 2022 and led both the $50M Series A and $40M Series A extension. Ascidian's business model is built on strategic research collaborations and licensing agreements with major pharmaceutical companies rather than direct product sales. Key deals include a June 2024 collaboration with Roche (up to $1.8B with $42M upfront) for neurological diseases and a June 2026 collaboration with Eli Lilly (up to $1.9B) for inherited kidney diseases, with Lilly and Roche handling clinical development, manufacturing, and commercialization for partnered indications. Manufacturing for ACDN-01 is supported by a January 2026 partnership with Forge Biologics using its cGMP FUEL platform. Customer segments are disease-defined (Stargardt/ABCA4 retinopathies, neurological diseases, monogenic kidney diseases, neuromuscular disorders), and pricing for any future approved therapeutics is not publicly disclosed as the company remains pre-revenue.

Ascidian Therapeutics firmographics

Firmographics
Name
Ascidian Therapeutics
Legal name
Ascidian Therapeutics, Inc.
Website
https://ascidian-tx.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Ascidian Therapeutics is a clinical-stage biotechnology company developing RNA exon editing therapeutics for genetic diseases. Its lead program, ACDN-01, targets Stargardt disease, with partnered programs in neurological and kidney diseases via Roche and Eli Lilly.
Ownership category
akta.pro rank

Ascidian Therapeutics industry classification

Industry
Product category
RNA Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNA exon editing
  • Gene therapy
  • RNA therapeutics
  • Clinical-stage biotechnology
  • Genetic disease treatment

Where Ascidian Therapeutics is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Ascidian Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing

Revenue model

  1. Strategic Partnerships and Licensing: Ascidian generates revenue through strategic research collaborations and licensing agreements with major pharmaceutical companies. These deals include upfront payments, development and commercial milestones, and royalties. Notable deals include Eli Lilly partnership (up to $1.9B for kidney diseases) and Roche partnership (up to $1.8B for neurological diseases).
  2. Future Drug Commercialization: Pre-revenue clinical stage company. Future revenue potential from commercialization of RNA exon editing therapeutics, including ACDN-01 for Stargardt disease and other pipeline programs in retinal, neurological, neuromuscular, and kidney disease indications.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels7 records

Ascidian Therapeutics product offering

Product offering

Core offering

Ascidian Therapeutics develops RNA exon editing therapeutics that replace disease-causing exons with wild-type exons at the RNA level using pre-mRNA trans-splicing technology. The platform enables treatment of large genes and genes with high mutational variance that are beyond the reach of existing DNA editing approaches, without modifying DNA or requiring foreign enzymes. Its lead candidate ACDN-01 targets ABCA4 retinopathies including Stargardt disease and is in Phase 1/2 clinical trials.

Product overview

Ascidian Therapeutics is developing a new class of RNA exon editing therapeutics to treat the underlying causes of genetic diseases. The company's platform technology enables editing and replacement of disease-causing RNA exons, producing full-length functional proteins. The lead therapeutic candidate ACDN-01 targets ABCA4 retinopathies including Stargardt disease and is in Phase 1/2 clinical trials. Additional programs include MSH3 for Huntington's disease and repeat expansion disorders. Partnered programs with Roche (neurological diseases) and Eli Lilly (kidney diseases) leverage the platform for additional therapeutic areas. The company operates with manufacturing partnerships including Forge Biologics for cGMP production.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Completed dose escalation portion of Phase 1/2 STELLAR trial with 10 adult participants ages 18-77
  • +2 more outcomes

Companies that use Ascidian Therapeutics

Customer profile

Named customers2 records

Segments4 records

Ascidian Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ascidian Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered flagship and core.

  • Eli LillyflagshipStrategic or Co-development Partner · 3 June 2026Global research and licensing agreement worth up to $1.9 billion for discovery and development of RNA exon editing therapies for kidney diseases. Ascidian leads discovery and selected preclinical activities while Lilly handles clinical development, manufacturing, and commercialization with exclusive rights to Ascidian's exon editing platform for undisclosed kidney disease targets. The partnership targets monogenic kidney diseases affecting over 3.5 million Americans.
  • Forge BiologicscoreTechnology or Integration · 7 January 2026Strategic manufacturing partnership for ACDN-01, Ascidian's lead RNA exon editing therapy for Stargardt disease. Forge Biologics provides process development, toxicology, and cGMP manufacturing services using proprietary FUEL platform at its 200,000-square-foot facility in Columbus, Ohio.
  • RocheflagshipStrategic or Co-development Partner · 18 June 2024Partnership potentially worth up to $1.8 billion for discovery and development of RNA exon editing therapeutics targeting neurological diseases. Ascidian received $42 million upfront payment from Roche for the neuro-focused collaboration, with potential additional milestone and royalty payments.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Ascidian Therapeutics competitors and assessment

Company assessment

Direct peers

  • ProQR Therapeutics: RNA-focused biotech developing Axiomer RNA editing technology and other RNA-based therapies for inherited retinal diseases and other genetic disorders. Direct competitor in RNA editing for ophthalmology indications.
  • Stoke Therapeutics: Clinical-stage biotech developing antisense oligonucleotide (ASO) therapies that increase protein production by modulating RNA splicing, including for genetic diseases such as Dravet syndrome. Direct competitor in RNA-targeted precision medicines for genetic disorders.
  • Wave Life Sciences: Clinical-stage RNA therapeutics company developing RNA editing and splice-modulating oligonucleotides for genetic diseases. Direct competitor in RNA-targeted modalities with similar programs in ophthalmology and rare genetic diseases.

Emerging players

  • SpliceBio: Clinical-stage company developing gene therapies based on protein trans-splicing (similar biological concept to Ascidian's RNA trans-splicing). Direct mechanistic parallel in exon replacement for genetic diseases.
  • Dyne Therapeutics: Clinical-stage company developing oligonucleotide therapies for muscle diseases, founded by Romesh Subramanian (also Ascidian's co-founder). Closely related through founder DNA and overlapping RNA-based therapeutic platform.
  • Shape Therapeutics: Preclinical RNA editing company leveraging AI/ML-based platform for RNA-targeted therapies. Competes with Ascidian's AI-enabled RNA discovery platform in computational RNA therapeutic design.
  • Korro Bio: Preclinical/early clinical company developing RNA editing therapeutics using ADAR-mediated approaches for genetic diseases. Competes with Ascidian in the RNA editing modality space, focused on high-throughput platform-based RNA editing.

Broad incumbents

  • Beam Therapeutics: Clinical-stage company developing base editing and prime editing therapies for genetic diseases. Competes in the broader genetic medicine editing space where Ascidian's exon editing is positioned as a complementary modality for large-gene targets.
  • Intellia Therapeutics: Clinical-stage CRISPR/Cas9 gene editing company developing in vivo and ex vivo therapies for genetic diseases. Represents the incumbent DNA-editing approach that Ascidian's RNA exon editing is positioned to complement for large-gene targets.
  • Editas Medicine: Clinical-stage CRISPR-based gene editing company with programs in ophthalmology and genetic diseases. Competes in the broader genomic medicine space where Ascidian's RNA exon editing offers a non-DNA editing alternative.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ascidian Therapeutics social profiles

Digital presence

Ascidian Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ascidian Therapeutics leadership team

Management profile

Number of profiles

Ascidian Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ascidian Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascidian Therapeutics

What does Ascidian Therapeutics do?

Ascidian Therapeutics develops RNA exon editing therapeutics that replace disease-causing exons with wild-type exons at the RNA level using pre-mRNA trans-splicing technology. The platform enables treatment of large genes and genes with high mutational variance that are beyond the reach of existing DNA editing approaches, without modifying DNA or requiring foreign enzymes. Its lead candidate ACDN-01 targets ABCA4 retinopathies including Stargardt disease and is in Phase 1/2 clinical trials.

Is Ascidian Therapeutics a public or private company?

Ascidian Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ascidian Therapeutics founded?

Ascidian Therapeutics was founded in 2022. It employs 11 to 50 people.

Where is Ascidian Therapeutics based?

Ascidian Therapeutics is headquartered in Boston, United States, in the North America region.

How does Ascidian Therapeutics make money?

Two revenue lines are on record. Strategic Partnerships and Licensing is the primary driver. The others are future Drug Commercialization.

Who are Ascidian Therapeutics's main competitors?

Direct peers on record are ProQR Therapeutics, Stoke Therapeutics and Wave Life Sciences. Emerging players are SpliceBio, Dyne Therapeutics, Shape Therapeutics and Korro Bio. Broad incumbents are Beam Therapeutics, Intellia Therapeutics and Editas Medicine.

Does Ascidian Therapeutics have an API?

No public API is recorded for Ascidian Therapeutics.

What industry is Ascidian Therapeutics in?

Ascidian Therapeutics's product category is RNA Therapeutics. Its primary akta.pro industry code is HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
STATUp and down the ladder: The latest comings and goingsFormation Bio appointed Michael Ehlers as its chief scientific officer and head of research and development. Ehlers previously served as CEO and president of Ascidian Therapeutics, a company he founded.citybizAscidian Therapeutics Names Daniel Rosan President as CEO Search BeginsAscidian Therapeutics has appointed Chief Financial Officer and Chief Business Officer Daniel Rosan as president, while founder Michael Ehlers steps down as president and chief executive officer but remains chair of the board of directors. The Boston-based biotech company will conduct a search for a permanent CEO as it advances its RNA exon editing pipeline, with lead candidate ACDN-01 for Stargardt disease progressing through clinical development. The transition reflects a common evolution for venture-backed biotechnology companies as they move from platform development toward clinical execution and commercialization planning.AijournAscidian Therapeutics Announces Leadership TransitionMichael Ehlers has stepped down as President and Chief Executive Officer of Ascidian Therapeutics and will continue as Chair of the Board of Directors, where he will guide scientific and company strategy. Daniel Rosan, who currently serves as Chief Financial Officer and Chief Business Officer, has been appointed President while retaining his existing responsibilities during the CEO succession process. The leadership transition comes as the company progresses its RNA exon editing pipeline, including lead program ACDN-01 for Stargardt disease, through clinical development.PR NewswireAscidian Therapeutics Announces Leadership TransitionAscidian Therapeutics announced a leadership transition as Michael Ehlers stepped down from his role as President and Chief Executive Officer, transitioning to serve as Chair of the Board of Directors to guide scientific and company strategy. Daniel Rosan, previously serving as Chief Financial Officer and Chief Business Officer, has been appointed President while retaining his existing responsibilities during the CEO succession process. The company states it will continue advancing its RNA exon editing platform and pipeline, including lead program ACDN-01 for Stargardt disease treatment, through clinical development.AdvfnAscidian Therapeutics Announces Leadership TransitionAscidian Therapeutics announced a leadership transition as Michael Ehlers stepped down from his role as President and Chief Executive Officer while continuing as Chair of the Board of Directors. Daniel Rosan, previously serving as Chief Financial Officer and Chief Business Officer, has been appointed President while retaining his existing responsibilities. The transition comes as the biotech company advances its RNA exon editing platform and lead program ACDN-01 for Stargardt disease through clinical development.BioSpaceLilly targets kidney disease with Ascidian’s RNA exon editors for up to $1.9BEli Lilly has entered into an RNA-focused alliance with Ascidian Therapeutics to develop treatments for kidney diseases, with the deal potentially worth up to $1.9 billion including upfront, development, and commercial milestones. Under the agreement, Ascidian will lead discovery and early lab work while Lilly assumes responsibility for subsequent preclinical and clinical development, manufacturing, and commercialization. The partnership reflects Lilly's aggressive reinvestment strategy, having already committed approximately $21 billion for partnerships by late April following its GLP-1 franchise generating over $36 billion in collective revenues last year.GenengnewsLilly, Ascidian Launch Up-to-$1.9B RNA Exon Editor Collaboration Targeting Inherited Kidney DiseasesEli Lilly has partnered with Ascidian Therapeutics to develop RNA exon editors for inherited kidney diseases, in a collaboration potentially worth more than $1.9 billion for the Boston biotech through upfront, development, and commercial milestone payments plus royalties. Ascidian will lead discovery and preclinical activities while Lilly oversees clinical development, manufacturing, and commercialization, with exclusive rights to the technology for undisclosed kidney disease targets. The deal continues Lilly's aggressive 2024 deal-making streak, which has included multiple biotech acquisitions and partnerships totaling billions, funded by cash from its GLP-1 franchise.AxiosAscidian lands up to $1.9B Lilly pact for kidney disease gene medicinesEli Lilly has entered into a deal with Ascidian Therapeutics worth up to $1.9 billion to develop genetic medicines for inherited kidney diseases. The partnership focuses on RNA rewriting technology, which Lilly believes may succeed where traditional gene therapy and gene editing approaches have struggled. This represents a significant investment in innovative kidney disease treatments by one of the world's largest pharmaceutical companies.BioPharma DiveLilly, Ascidian link up in RNA exon editing pactEli Lilly and Ascidian Therapeutics announced a research collaboration worth up to $1.9 billion to develop treatments for genetically driven kidney diseases using Ascidian's RNA exon editing platform, which replaces damaged RNA segments to enable functional protein production. The deal includes an upfront payment, development and commercial milestones, and tiered royalties, with the companies targeting the more than 60 genetic diseases affecting kidneys and over 3.5 million Americans with severe inherited kidney disease. Ascidian already has an early-stage treatment for Stargardt eye disease in human testing and a separate 2024 collaboration with Roche valued at up to $1.8 billion.FierceBiotechAscidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseasesAscidian Therapeutics and Eli Lilly have signed a research collaboration worth up to $1.9 billion to discover and develop RNA exon editing therapeutics for genetic kidney diseases. Under the agreement, Ascidian will lead discovery and selected preclinical activities while Lilly handles clinical development, manufacturing, and commercialization of potential products. The deal follows Ascidian's 2024 partnership with Roche and comes as the company advances its lead asset ACDN-01, an RNA exon editing candidate for Stargardt disease, in a Phase 1/2 clinical trial.